2024-511440-76-00招募中1 期
Intralesional Cemiplimab for Adult Patients with Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma
Regeneron Pharmaceuticals Inc.5 个研究点 分布在 1 个国家目标入组 5 人开始时间: 2024年9月5日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 5
- 试验地点
- 5
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Medical Affairs
Scientific
Regeneron Pharmaceuticals Inc.
研究点 (5)
Loading locations...
相似试验
招募中
2 期
Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer (CERPASS)2024-512652-38-00Replimune Group Inc.143
招募中
2 期
Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell CarcinomaNCT07281417National Cancer Institute (NCI)108
招募中
2 期
A Randomized Phase II Trial of Cemiplimab Plus OSE2101 ( TEDOPI®) as Maintenance Therapy in ctDNA Positive NSCL. The Cemited Study.NSCLCNCT07264673Fondazione Ricerca Traslazionale160
尚未招募
2 期
Hyperprogression in PD-L1 ≥ 50% NSCLC: a Biomarker Guided Phase 2 TrialNCT07274384Università Vita-Salute San Raffaele74
招募中
2 期
Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal CancerColorectal CancerNCT07281768Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins66